RETA (Reata) Net earnings per share (EPS TTM)

Reata (RETA) - corporate logo

Effective management of the drug Skyclarys has provided Reata Pharmaceuticals (RETA) with a stable cash flow. The 12-month YoY change in net income per share visualizes this success, where the value indicates the status of current profitability. The business relies on steady, non-seasonal demand within the neurology sector. High margins from the global sale of proprietary medicines guarantee excellent scalability.

Reata - RETA Earnings per share for the last twelve months (period 07/04/2022 - 11/17/2026)

RETA (Reata Pharmaceuticals Inc): analytical breakdowns and indicator data

- price and consensus price forecast:
- business market valuation indicators:
Fundamental company valuation:RETA Reata
Flagship merchandise of Reata Pharmaceuticals, Inc.

This metric measures the net income per share dynamics over twelve months, reflecting the business scaling rate. Growth in this indicator confirms the strategy's effectiveness, while a slowdown signals a risk of asset overvaluation. By analyzing the rolling annual growth of net income per share, an investor determines the value momentum phase. For Reata Pharmaceuticals (RETA), this confirms the financial results stemming from the FDA approval of a unique drug. The successful merger with Biogen solidifies this trend by capitalizing on management's achievements.

Direct competitors

Net earnings per one share for the last twelve months Jazz Pharma|CYTK (Cytokinetics Inc.) - Net earnings per share for the last 12 months|PTC Bio (PTCT) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months Scholar Rock|CNTA: Earnings per share for the trailing year|Earnings per share for the last twelve months Dyne Therapeutics (DYN)|EWTX - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Rapport Pharma RAPP|Alumis Pharma - Earnings per share for the last twelve months|ZVRA - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Contineum Therapeutics, Inc.|LRMR: Net earnings per share (EPS TTM)|Net earnings per share for the trailing year Capricor Therapeutics CAPR|Net earnings per share for the last 12 months TRDA|Net earnings per one share for the last twelve months Channel PTHS|Earnings per share for the last twelve months MediciNova Inc. (MNOV)|SER - Net earnings per one share for the last twelve months|Net earnings per share (EPS TTM) BTAI (BioXcel Therapeutics Inc)|ProMIS Neurosciences (PMN) - Net earnings per one share for the last twelve months|Apimeds Pharmaceuticals, Inc. - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months AEON Biopharma, Inc.|NLSP (NLS Pharma) - Net earnings per share for the last 12 months|Earnings per share for the last 12 months BNOX|Earnings per share for the last twelve months FSD Pharma